Therapeutics News

SAN DIEGO — In this video perspective, Healio Dermatology Chief Medical Editor Joel M. Gelfand, MD, MSCE, discusses highlights from the LITE study on home vs. office-based phototherapy for plaque or guttate psoriasis.

SAN DIEGO — In this video perspective, Menas Kizoulis, senior director of global scientific engagement at Kenvue, discusses the company’s latest research presented at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — In a real-world setting, treatment with home-based phototherapy was noninferior to office phototherapy for people with plaque or guttate psoriasis, with both options safe and efficacious, according to a speaker here.

SAN DIEGO — The Skin of Color Society has awarded innovation grants to two finalists at the 20th Annual Skin of Color Society Scientific Symposium.

Arcutis has entered into a licensing agreement with Sato Pharmaceutical Co. Ltd. to develop, manufacture and commercialize topical roflumilast in Japan for the treatment of multiple skin conditions, according to a company press release.

Using the efficiency frontier approach to negotiate prices for plaque psoriasis biologics may lead to substantial price reductions that better align with clinical benefits in the U.S., according to a study.

The use of intravenous antibiotics, specifically ertapenem, was associated with improvement in inflammatory markers in patients with hidradenitis suppurativa, according to a study.

The FDA’s broad indication for the use of beremagene geperpavec therapy for the treatment of dystrophic epidermolysis bullosa may have large financial implications for payers, according to a study.

Patients with plaque or guttate psoriasis treated with at-home phototherapy experienced similar benefits to those treated in-office, according to topline study data.

Ophthalmic application of beremagene geperpavec was successful in treating recurrent cicatrizing conjunctivitis in one patient with dystrophic epidermolysis bullosa, according to a study.